Literature DB >> 31434614

Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer.

Vaibhav Shukla1, Vinay Koshy Varghese1, Shama Prasada Kabekkodu1, Sandeep Mallya2, Sanjiban Chakrabarty1, Pradyumna Jayaram1, Deeksha Pandey3, Sourjya Banerjee4, Krishna Sharan5, Kapaettu Satyamoorthy6.   

Abstract

OBJECTIVE: The altered miRNAs expression in cervical cancer tissue can be a critical player during tumorigenesis, may contribute to tumor cell heterogeneity and may determine distinct phenotypes within the tumor. Recent studies have highlighted the role of circulating miRNAs as a minimally-invasive biomarker and its potential as biosignature to complement routine tissue-based procedures.
METHODS: In order to determine whether miRNAs in serum can indicate changes in cervical tissue specimens, we performed small RNA sequencing and selected miRNAs were validated using qRT-PCR in serum and tissue specimens (n = 115). Further, luciferase assay were performed to investigate the interactions between hsa-miR-409-3p and hsa-miR-454-3p binding sites on 3'UTR region of MTF2 and ST18 respectively.
RESULTS: We have identified a total of 14 differentially expressed miRNAs common in serum and tissue specimens. Among them, hsa-miR-17-5p, hsa-miR-32-5p and hsa-miR-454-3p were upregulated while, hsa-miR-409-3p was downregulated in serum and tissue of cervical cancer subjects. Our in-silico small RNA sequencing data analysis identified isomiRs and classified miRNA into clusters and subtypes (exonic, intronic and intergenic) with respect to the expression status in serum and tissue specimens. Expression level of hsa-miR-409-3p and hsa-miR-454-3p were inversely correlated with their target genes MTF2 and ST18 levels respectively in human cervical cancer specimens. Luciferase assay demonstrated that hsa-miR-409-3p and hsa-miR-454-3p functionally interacts with 3'-UTR of MTF2 and ST18 respectively to decrease their activity.
CONCLUSION: Our results support the significant role of circulating miRNAs in disease dissemination and their potential utility as biosignatures of clinical relevance.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarker; Cervical cancer; Serum specimen; Small RNA sequencing; microRNA

Mesh:

Substances:

Year:  2019        PMID: 31434614     DOI: 10.1016/j.ygyno.2019.08.012

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Tumor Suppressor 4.1N/EPB41L1 is Epigenetic Silenced by Promoter Methylation and MiR-454-3p in NSCLC.

Authors:  Qin Yang; Lin Zhu; Mao Ye; Bin Zhang; Peihe Zhan; Hui Li; Wen Zou; Jing Liu
Journal:  Front Genet       Date:  2022-06-20       Impact factor: 4.772

2.  Identification key genes, key miRNAs and key transcription factors of lung adenocarcinoma.

Authors:  Jinghang Li; Zhi Li; Sheng Zhao; Yuanyuan Song; Linjie Si; Xiaowei Wang
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

Review 3.  miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools.

Authors:  Leonardo J Galvão-Lima; Antonio H F Morais; Ricardo A M Valentim; Elio J S S Barreto
Journal:  Biomed Eng Online       Date:  2021-02-16       Impact factor: 2.819

4.  miR-17-5p accelerates cervical cancer cells migration and invasion via the TIMP2/MMPs signaling cascade.

Authors:  Min Zou; Qiong Zhang
Journal:  Cytotechnology       Date:  2021-06-23       Impact factor: 2.040

Review 5.  The Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer.

Authors:  Maria Lina Tornesello; Raffaella Faraonio; Luigi Buonaguro; Clorinda Annunziata; Noemy Starita; Andrea Cerasuolo; Francesca Pezzuto; Anna Lucia Tornesello; Franco Maria Buonaguro
Journal:  Front Oncol       Date:  2020-02-20       Impact factor: 6.244

6.  MicroRNA-409-3p Targeting at ATXN3 Reduces the Apoptosis of Dopamine Neurons Based on the Profile of miRNAs in the Cerebrospinal Fluid of Early Parkinson's Disease.

Authors:  Xuling Tan; Junjian Hu; Fengyu Ming; Lingling Lv; Weiqian Yan; Xinke Peng; Rongrong Bai; Qile Xiao; Hainan Zhang; Beisha Tang; Chunyu Wang; Jieqiong Tan
Journal:  Front Cell Dev Biol       Date:  2022-01-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.